[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100535293":3},{"organization":4,"armGroups":7,"interventions":20,"overallOfficials":32,"centralContacts":40,"locations":49,"responsibleParty":82,"collaborators":84,"id":86,"slug":87,"hasResults":88,"nctId":89,"briefTitle":90,"officialTitle":91,"acronym":92,"eligibilityCriteria":93,"healthyVolunteers":88,"sex":94,"minAge":95,"maxAge":31,"enrollmentInfo":96,"targetDuration":31,"studyType":99,"phases":100,"briefSummary":102,"conditions":103,"keywords":106,"overallStatus":52,"whyStopped":31,"lastUpdateSubmitDate":111,"lastUpdatePostDateStruct":112,"startDateStruct":115,"completionDateStruct":117,"leadSponsor":119,"locationsCount":120},{"fullName":5,"class":6},"National Taiwan University Hospital","OTHER",[8,14],{"label":9,"type":10,"description":11,"interventionNames":12},"empagliflozin","EXPERIMENTAL","Jardiance, 25 mg, QD, for 6 months",[13],"Drug: Empagliflozin 25 MG",{"label":15,"type":16,"description":17,"interventionNames":18},"Placebo","PLACEBO_COMPARATOR","QD, for 6 months",[19],"Drug: Placebo",[21,28],{"type":22,"name":23,"description":24,"armGroupLabels":25,"otherNames":26},"DRUG","Empagliflozin 25 MG","The medication will be packed in a customized sealed jar and labeled on the exterior of the jar.",[9],[27],"Jardiance 25 MG",{"type":22,"name":15,"description":29,"armGroupLabels":30,"otherNames":31},"The placebo tablet is manufactured by Prince Pharmaceutical Co., Ltd, a leading manufacturer of nutritional supplements with certifications including cGMP, GMP, ISO, and HACCP. The Prince Pharmaceutical also provides Original Equipment Manufacturing (OEM)\u002FOriginal Design Manufacturing (ODM) services for a wide array of tablet shapes, and post-processing techniques such as film coating and sugar coating.",[15],null,[33,37],{"name":34,"affiliation":35,"role":36},"Donna SH Lin, MD","Shin Kong Wu Ho-Su Memorial Hospital","PRINCIPAL_INVESTIGATOR",{"name":38,"affiliation":39,"role":36},"Chih-Cheng Wu, MD. PhD","National Taiwan University Hsin-Chu Hospital",[41,45],{"name":34,"role":42,"phone":43,"phoneExt":31,"email":44},"CONTACT","+886912902379","Donna.lin24@gmail.com",{"name":46,"role":42,"phone":47,"phoneExt":31,"email":48},"Hao-Yun Lo, MD","+886972234640","limoonby@gmail.com",[50,69],{"facility":51,"status":52,"city":53,"state":31,"zip":54,"country":55,"countryCode":56,"cosmosGeoPoint":57,"geoPoint":62,"contacts":63},"National Taiwan University Hospital Hsinchu Branch","RECRUITING","Hsinchu","300","Taiwan","TW",{"type":58,"coordinates":59},"Point",[60,61],120.96861,24.80361,{"lat":61,"lon":60},[64,68],{"name":65,"role":42,"phone":66,"phoneExt":31,"email":67},"Chih-Cheng Wu, PhD","03 532 6151","chihchengwumd@gmail.com",{"name":65,"role":36,"phone":31,"phoneExt":31,"email":31},{"facility":35,"status":52,"city":70,"state":31,"zip":71,"country":55,"countryCode":56,"cosmosGeoPoint":72,"geoPoint":76,"contacts":77},"Taipei","111",{"type":58,"coordinates":73},[74,75],121.52639,25.05306,{"lat":75,"lon":74},[78,81],{"name":34,"role":42,"phone":79,"phoneExt":31,"email":80},"0912902379","donna.lin24@gmail.com",{"name":34,"role":36,"phone":31,"phoneExt":31,"email":31},{"type":83,"investigatorFullName":31,"investigatorTitle":31,"investigatorAffiliation":31,"oldNameTitle":31,"oldOrganization":31},"SPONSOR",[85],{"name":35,"class":6},"100535293","phase-4-empagliflozin-in-heart-failure-with-preserved-ejection-fraction-and-end-stage-renal-disease-100535293",false,"NCT06249945","EMPAgliflozin in Heart Failure With PReserved Ejection Fraction and End Stage Renal Disease","The Safety and Efficacy of Empagliflozin in Patients With End-stage Renal Disease and Heart Failure With Preserved Ejection Fraction - a Randomized Controlled Trial","EMPA-PRED","Inclusion Criteria:\n\n* Age ≥20 years old\n* ESRD under chronic, maintenance dialysis with stable dry weight for the past 6 months\n* Prior diagnosis of HFpEF, as defined by a score of ≥5 on the HFA-PEFF diagnostic algorithm.\n\nExclusion Criteria:\n\n* Age \\\u003C20 years old\n* Ongoing pregnancy\n* NYHA class IV heart failure\n* Any hospitalization for heart failure within the past month Ongoing acute urinary tract infection at the time of screening\n* Known acute genital infection\n* Severe peripheral artery disease (Rutherford category 4-6)\n* Acute coronary syndrome, stroke or transient ischemic attack within the past month\n* Recent initiation of chronic maintenance hemodialysis within 6 months\n* Adjustment of dry weight with changes greater than 5% of body weight within the past month\n* Documented left ventricular ejection fraction =\\\u003C40% by any imaging modality within 1 month of screening\n* Refused informed consent","ALL","20 Years",{"count":97,"type":98},150,"ESTIMATED","INTERVENTIONAL",[101],"PHASE4","The presence of CKD has been linked to the development of HFpEF. Currently, the treatment for HFpEF is limited. SGLT2i are one of the few drug classes that have proven efficacy in HFpEF in randomized controlled trials. The results of mechanistic studies suggest that the benefits of SGLT2i on diastolic heart failure are independent of their glycosuric actions and may still be present in anuric subjects. Despite the significance of HFpEF in patients with CKD, patients with advanced kidney disease have been excluded from studies investigating anti-heart failure drugs. The effects of SGLT2i in patients under maintenance dialysis are largely unknown. Past pharmacokinetics and pharmacodynamics studies on empagliflozin in patients with end-stage renal disease (ESRD) demonstrated that the use of empagliflozin in patients with ESRD seemed safe, yet its efficacy remains to be explored.",[104,105],"Heart Failure With Preserved Ejection Fraction","End Stage Renal Disease on Dialysis",[107,108,109,110,9],"end-stage renal disease","sodium-glucose co-transporter 2 inhibitors","heart failure","diastolic function","2024-12-10",{"date":113,"type":114},"2024-12-16","ACTUAL",{"date":116,"type":114},"2024-03-05",{"date":118,"type":98},"2030-12-31",{"name":5,"class":6},2]